Jim Zhen Wu

The Ark — Ireland

Medicine · Health Sciences

34h-index2.7kcitations74works2.42yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hepatitis C virus research(26), HIV/AIDS drug development and treatment(16), Biochemical and Molecular Research(13), Respiratory viral infections research(10), Hepatitis B Virus Studies(8)

Publications74 total

Molecular mechanism of ziresovir targeting the fusion glycoprotein of respiratory syncytial virus
PLoS Pathogens·2026Open Access
Efficacy and safety of ziresovir in hospitalised infants aged 6 months or younger with respiratory syncytial virus infection in China: findings from a phase 3 randomised trial with 24-month follow-up
The Lancet Child & Adolescent Health·2025· 10 cited
Broad antifibrotic activities of AK3280 in pulmonary, hepatic, cardiac, and skin fibrosis animal models
International Immunopharmacology·2025· 1 cited
Ziresovir Offers New Hope for Treating Respiratory Syncytial Virus Infections
2025Open Access
Novel small-molecule inhibitors of SARS-CoV-2 main protease with nanomolar antiviral potency
Journal of Infection·2024· 1 citedOpen Access
Current state and challenges in respiratory syncytial virus drug discovery and development
Antiviral Research·2023· 20 cited
A protective human antibody against respiratory syncytial virus by targeting a prefusion epitope across sites IV and V of the viral fusion glycoprotein
hLife·2023· 13 citedOpen Access
Supplementary Table 1 from Polo-like Kinase Inhibitor Ro5203280 Has Potent Antitumor Activity in Nasopharyngeal Carcinoma
2023Open Access
Supplementary Figure 4 from Polo-like Kinase Inhibitor Ro5203280 Has Potent Antitumor Activity in Nasopharyngeal Carcinoma
2023Open Access
Supplementary Figure 1 from Polo-like Kinase Inhibitor Ro5203280 Has Potent Antitumor Activity in Nasopharyngeal Carcinoma
2023Open Access
Supplementary Figure Legend from Polo-like Kinase Inhibitor Ro5203280 Has Potent Antitumor Activity in Nasopharyngeal Carcinoma
2023Open Access
Supplementary Figure 2 from Polo-like Kinase Inhibitor Ro5203280 Has Potent Antitumor Activity in Nasopharyngeal Carcinoma
2023Open Access
Data from Polo-like Kinase Inhibitor Ro5203280 Has Potent Antitumor Activity in Nasopharyngeal Carcinoma
2023Open Access
Supplementary Figure 3 from Polo-like Kinase Inhibitor Ro5203280 Has Potent Antitumor Activity in Nasopharyngeal Carcinoma
2023Open Access
Supplementary Figure Legend from Polo-like Kinase Inhibitor Ro5203280 Has Potent Antitumor Activity in Nasopharyngeal Carcinoma
2023Open Access
Supplementary Figure 1 from Polo-like Kinase Inhibitor Ro5203280 Has Potent Antitumor Activity in Nasopharyngeal Carcinoma
2023Open Access
Supplementary Table 1 from Polo-like Kinase Inhibitor Ro5203280 Has Potent Antitumor Activity in Nasopharyngeal Carcinoma
2023Open Access
Supplementary Figure 2 from Polo-like Kinase Inhibitor Ro5203280 Has Potent Antitumor Activity in Nasopharyngeal Carcinoma
2023Open Access
Supplementary Figure 4 from Polo-like Kinase Inhibitor Ro5203280 Has Potent Antitumor Activity in Nasopharyngeal Carcinoma
2023Open Access
Supplementary Figure 3 from Polo-like Kinase Inhibitor Ro5203280 Has Potent Antitumor Activity in Nasopharyngeal Carcinoma
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Zhi Hong(17), Nanhua Yao(12), Gary Larson(12), Shunqi Yan(9), T.C. Appleby(9), Robert Hamatake(8), Guozhi Tang(7), Wengang Yang(6), Jae Hoon Shim(6), Weidong Zhong(6), I. Wayne Cheney(5), Heli Walker(5), Hong C. Shen(5), Zongxing Qiu(5), Xianfeng Lin(5), Lisha Wang(4), Guang Yang(4), Zhi Hong(4), Shaohua Li(4), Frank Rong(3)